Included in the formulation
Pharmacodynamics:Reflexively stimulates the mucociliary transport of the rhinobronchial epithelium.
Pharmacokinetics:Elimination by the kidneys.
Indications:As an expectorant for inflammatory diseases of the respiratory tract.
X.J20-J22.J22 Acute respiratory infection of lower respiratory tract, unspecified
X.J00-J06.J06.9 Acute upper respiratory tract infection, unspecified
X.J00-J06.J06 Acute upper respiratory tract infections of multiple and unspecified sites
X.J20-J22 Other acute respiratory infections of the lower respiratory tract
X.J00-J06.J06.8 Other acute upper respiratory tract infections of multiple localization
X.J00-J06 Acute respiratory infections of the upper respiratory tract
Contraindications:Hypersensitivity.
Carefully:Children under 18 years of age, pregnancy, breast-feeding. Elderly age, renal and hepatic insufficiency.
Pregnancy and lactation:FDA recommendation category C.
No violations were found. It is necessary to relate the risk and benefit, as possible systemic action when ingestion. With constant intake of - the risk of developing systemic alkalosis. Reabsorption of sodium ions can cause swelling and weight gain.Studies of the parenteral form of administration on humans and animals have not been carried out. There is no information on the penetration into breast milk. Complications in humans are not recorded.
Dosing and Administration:In powders, solutions, potions 0.2-0.5 g 3-4 times a day.
Side effects:Not described.
Interaction:Not described.
Special instructions:None.